Review



human hepatoma cell lines hepg2  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC human hepatoma cell lines hepg2
    SHBs is symmetrically dimethylated at arginine 169. (A–C) Huh7 and <t>HepG2</t> cells were transfected with plasmids encoding SHBs–Strep–Flag or Strep–Flag control. Strep pull–down (IP:Strep) was performed, followed by Western blot (WB) with antibodies against (A) monomethylarginine (MMA), (B) asymmetric dimethylarginine (ADMA), or (C) symmetric dimethylarginine (SDMA). SHBs in the IP fraction and SHBs/β–actin in input lysates are shown as controls. (D) Cells expressing SHBs–Strep–Flag were treated with adenosine dialdehyde (ADOX, 40 μM) for 36 h, followed by Strep pull–down and WB for SDMA and SHBs. Densitometric ratios (SDMA/IP–SHBs and SHBs/β–actin) are shown above/below the blots. (E) Huh7 cells were transfected with plasmids encoding SHBs–Strep–Flag or the indicated R→K mutants (R73K, R78K, R79K, R169K). SDMA on immunoprecipitated SHBs was assessed by Strep pull–down and WB; densitometric SDMA/IP–SHBs ratios are shown above the blots. (F–G) HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag (F) and SHBs/R169A–Strep–Flag (G) and analyzed by Strep pull–down and WB as in (E).
    Human Hepatoma Cell Lines Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 29071 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hepatoma cell lines hepg2/product/ATCC
    Average 99 stars, based on 29071 article reviews
    human hepatoma cell lines hepg2 - by Bioz Stars, 2026-05
    99/100 stars

    Images

    1) Product Images from "PRMT5–mediated symmetric dimethylation of SHBs at Arg169 stabilizes SHBs and promotes angiogenesis and tumor growth"

    Article Title: PRMT5–mediated symmetric dimethylation of SHBs at Arg169 stabilizes SHBs and promotes angiogenesis and tumor growth

    Journal: Tumour Virus Research

    doi: 10.1016/j.tvr.2026.200340

    SHBs is symmetrically dimethylated at arginine 169. (A–C) Huh7 and HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or Strep–Flag control. Strep pull–down (IP:Strep) was performed, followed by Western blot (WB) with antibodies against (A) monomethylarginine (MMA), (B) asymmetric dimethylarginine (ADMA), or (C) symmetric dimethylarginine (SDMA). SHBs in the IP fraction and SHBs/β–actin in input lysates are shown as controls. (D) Cells expressing SHBs–Strep–Flag were treated with adenosine dialdehyde (ADOX, 40 μM) for 36 h, followed by Strep pull–down and WB for SDMA and SHBs. Densitometric ratios (SDMA/IP–SHBs and SHBs/β–actin) are shown above/below the blots. (E) Huh7 cells were transfected with plasmids encoding SHBs–Strep–Flag or the indicated R→K mutants (R73K, R78K, R79K, R169K). SDMA on immunoprecipitated SHBs was assessed by Strep pull–down and WB; densitometric SDMA/IP–SHBs ratios are shown above the blots. (F–G) HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag (F) and SHBs/R169A–Strep–Flag (G) and analyzed by Strep pull–down and WB as in (E).
    Figure Legend Snippet: SHBs is symmetrically dimethylated at arginine 169. (A–C) Huh7 and HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or Strep–Flag control. Strep pull–down (IP:Strep) was performed, followed by Western blot (WB) with antibodies against (A) monomethylarginine (MMA), (B) asymmetric dimethylarginine (ADMA), or (C) symmetric dimethylarginine (SDMA). SHBs in the IP fraction and SHBs/β–actin in input lysates are shown as controls. (D) Cells expressing SHBs–Strep–Flag were treated with adenosine dialdehyde (ADOX, 40 μM) for 36 h, followed by Strep pull–down and WB for SDMA and SHBs. Densitometric ratios (SDMA/IP–SHBs and SHBs/β–actin) are shown above/below the blots. (E) Huh7 cells were transfected with plasmids encoding SHBs–Strep–Flag or the indicated R→K mutants (R73K, R78K, R79K, R169K). SDMA on immunoprecipitated SHBs was assessed by Strep pull–down and WB; densitometric SDMA/IP–SHBs ratios are shown above the blots. (F–G) HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag (F) and SHBs/R169A–Strep–Flag (G) and analyzed by Strep pull–down and WB as in (E).

    Techniques Used: Transfection, Control, Western Blot, Expressing, Immunoprecipitation

    PRMT interacts with SHBs. (A) Huh7 cells were co–transfected with plasmids encoding SHBs–Strep–Flag (or Strep–Flag control) together with Flag–PRMT9. Strep pull–down was followed by WB with anti–Flag and anti–SHBs to assess co–precipitation. (B) Huh7 and HepG2 cells were co–transfected with plasmids encoding SHBs–Strep–Flag (or Strep–Flag control) together with Flag–PRMT5 and analyzed by Strep pull–down and WB as in (A). (C) Huh7 and HepG2 cells were co–transfected with plasmids encoding Strep–Flag–PRMT5 and SHBs–myc. Strep pull–down was performed and precipitates were immunoblotted for SHBs and Flag to validate the interaction. (D) Direct interaction between SHBs and PRMT5 was tested by GST pull–down. Purified GST or GST–PRMT5 (Coomassie–stained gel, left) was incubated with in vitro–translated SHBs–Flag, and bound SHBs was detected by WB using anti–Flag (right). (E) Confocal microscopy showing subcellular localization of SHBs (red) and PRMT5 (green) with nuclear DAPI staining (blue). Merged images and a representative line–scan fluorescence intensity profile (right) are shown.
    Figure Legend Snippet: PRMT interacts with SHBs. (A) Huh7 cells were co–transfected with plasmids encoding SHBs–Strep–Flag (or Strep–Flag control) together with Flag–PRMT9. Strep pull–down was followed by WB with anti–Flag and anti–SHBs to assess co–precipitation. (B) Huh7 and HepG2 cells were co–transfected with plasmids encoding SHBs–Strep–Flag (or Strep–Flag control) together with Flag–PRMT5 and analyzed by Strep pull–down and WB as in (A). (C) Huh7 and HepG2 cells were co–transfected with plasmids encoding Strep–Flag–PRMT5 and SHBs–myc. Strep pull–down was performed and precipitates were immunoblotted for SHBs and Flag to validate the interaction. (D) Direct interaction between SHBs and PRMT5 was tested by GST pull–down. Purified GST or GST–PRMT5 (Coomassie–stained gel, left) was incubated with in vitro–translated SHBs–Flag, and bound SHBs was detected by WB using anti–Flag (right). (E) Confocal microscopy showing subcellular localization of SHBs (red) and PRMT5 (green) with nuclear DAPI staining (blue). Merged images and a representative line–scan fluorescence intensity profile (right) are shown.

    Techniques Used: Transfection, Control, Purification, Staining, Incubation, In Vitro, Confocal Microscopy, Fluorescence

    PRMT5 stabilizes SHBs protein expression in an Arg169–dependent manner. (A) Huh7 and HepG2 cells were co–transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag together with increasing amounts of Flag–PRMT5 (0, 1, 3 μg). Whole–cell lysates were immunoblotted for SHBs, Flag, and β–actin; SHBs/β–actin ratios are shown above the blots. (B) Cells expressing SHBs–Strep–Flag or SHBs/R169K–Strep–Flag were transfected with NC or PRMT5 siRNAs (#1, #2). Lysates were immunoblotted for SHBs, PRMT5, and β–actin; SHBs/β–actin ratios are shown. (C–D) Cycloheximide (CHX) chase assays in (C) Huh7 and (D) HepG2 cells. Cells expressing SHBs or SHBs/R169K with vector or Flag–PRMT5 were treated with CHX for the indicated times (0–120 min), followed by WB for SHBs, Flag, and β–actin. Plots show relative SHBs levels normalized to time 0 with fitted linear regression (equations displayed). (E) HepG2 cells were co–transfected with plasmids encoding SHBs–Strep, HA–K48Ub, together with or without Flag–PRMT5, and treated with MG132 (20 μM) for 8 h, the ubiquitination levels of SHBs was evaluated via ubiquitination assay analysis. (F) HepG2 cells were co–transfected with plasmid encoding SHBs–Strep and TRIM21–myc (or control vector) and Flag–PRMT5 (or control vector), the cell lysates were subjected to immunoprecipitation using Strep–Tactin and analyzed by immunoblotting.
    Figure Legend Snippet: PRMT5 stabilizes SHBs protein expression in an Arg169–dependent manner. (A) Huh7 and HepG2 cells were co–transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag together with increasing amounts of Flag–PRMT5 (0, 1, 3 μg). Whole–cell lysates were immunoblotted for SHBs, Flag, and β–actin; SHBs/β–actin ratios are shown above the blots. (B) Cells expressing SHBs–Strep–Flag or SHBs/R169K–Strep–Flag were transfected with NC or PRMT5 siRNAs (#1, #2). Lysates were immunoblotted for SHBs, PRMT5, and β–actin; SHBs/β–actin ratios are shown. (C–D) Cycloheximide (CHX) chase assays in (C) Huh7 and (D) HepG2 cells. Cells expressing SHBs or SHBs/R169K with vector or Flag–PRMT5 were treated with CHX for the indicated times (0–120 min), followed by WB for SHBs, Flag, and β–actin. Plots show relative SHBs levels normalized to time 0 with fitted linear regression (equations displayed). (E) HepG2 cells were co–transfected with plasmids encoding SHBs–Strep, HA–K48Ub, together with or without Flag–PRMT5, and treated with MG132 (20 μM) for 8 h, the ubiquitination levels of SHBs was evaluated via ubiquitination assay analysis. (F) HepG2 cells were co–transfected with plasmid encoding SHBs–Strep and TRIM21–myc (or control vector) and Flag–PRMT5 (or control vector), the cell lysates were subjected to immunoprecipitation using Strep–Tactin and analyzed by immunoblotting.

    Techniques Used: Expressing, Transfection, Plasmid Preparation, Ubiquitin Proteomics, Control, Immunoprecipitation, Western Blot

    Arg169 symmetric dimethylation is required for SHBs–driven angiogenesis and tumor growth. (A) WB analysis of SHBs and BIP expression in stably transduced Huh7 and HepG2 cells (Vector, SHBs, and SHBs/R169K). (B) ELISA measurement of VEGFA levels in the supernatants of Huh7/HepG2–Vector, Huh7/HepG2–SHBs, or Huh7/HepG2–SHBs/R169K cells. (C) Endothelial tube formation assay. EA.hy926 cells were cultured with conditioned media (CM) from Huh7 or HepG2 stable lines (Vector, SHBs, SHBs/R169K). Representative images and quantification of mesh numbers are shown. (D) Transwell migration assay. EA.hy926 cells were assessed for migration in response to CM from the indicated stable lines. Representative images and quantification of migrated cell numbers per field are shown. (E) Representative images of excised subcutaneous xenograft tumors derived from Huh7–Vector, Huh7–SHBs, or Huh7–SHBs/R169K cells. (F) Tumor growth curves (tumor volume over time) for the indicated xenograft groups. (G) Tumor weights at endpoint. (H) Representative immunohistochemical staining of xenograft tumors for CD31 and SHBs, with quantification of microvessel density (MVD) based on CD31 staining. Data are presented as mean ± SD; ∗ P < 0.05 as indicated.
    Figure Legend Snippet: Arg169 symmetric dimethylation is required for SHBs–driven angiogenesis and tumor growth. (A) WB analysis of SHBs and BIP expression in stably transduced Huh7 and HepG2 cells (Vector, SHBs, and SHBs/R169K). (B) ELISA measurement of VEGFA levels in the supernatants of Huh7/HepG2–Vector, Huh7/HepG2–SHBs, or Huh7/HepG2–SHBs/R169K cells. (C) Endothelial tube formation assay. EA.hy926 cells were cultured with conditioned media (CM) from Huh7 or HepG2 stable lines (Vector, SHBs, SHBs/R169K). Representative images and quantification of mesh numbers are shown. (D) Transwell migration assay. EA.hy926 cells were assessed for migration in response to CM from the indicated stable lines. Representative images and quantification of migrated cell numbers per field are shown. (E) Representative images of excised subcutaneous xenograft tumors derived from Huh7–Vector, Huh7–SHBs, or Huh7–SHBs/R169K cells. (F) Tumor growth curves (tumor volume over time) for the indicated xenograft groups. (G) Tumor weights at endpoint. (H) Representative immunohistochemical staining of xenograft tumors for CD31 and SHBs, with quantification of microvessel density (MVD) based on CD31 staining. Data are presented as mean ± SD; ∗ P < 0.05 as indicated.

    Techniques Used: Expressing, Stable Transfection, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Endothelial Tube Formation Assay, Cell Culture, Transwell Migration Assay, Migration, Derivative Assay, Immunohistochemical staining, Staining



    Similar Products

    99
    ATCC human hepatoma cell lines hepg2
    SHBs is symmetrically dimethylated at arginine 169. (A–C) Huh7 and <t>HepG2</t> cells were transfected with plasmids encoding SHBs–Strep–Flag or Strep–Flag control. Strep pull–down (IP:Strep) was performed, followed by Western blot (WB) with antibodies against (A) monomethylarginine (MMA), (B) asymmetric dimethylarginine (ADMA), or (C) symmetric dimethylarginine (SDMA). SHBs in the IP fraction and SHBs/β–actin in input lysates are shown as controls. (D) Cells expressing SHBs–Strep–Flag were treated with adenosine dialdehyde (ADOX, 40 μM) for 36 h, followed by Strep pull–down and WB for SDMA and SHBs. Densitometric ratios (SDMA/IP–SHBs and SHBs/β–actin) are shown above/below the blots. (E) Huh7 cells were transfected with plasmids encoding SHBs–Strep–Flag or the indicated R→K mutants (R73K, R78K, R79K, R169K). SDMA on immunoprecipitated SHBs was assessed by Strep pull–down and WB; densitometric SDMA/IP–SHBs ratios are shown above the blots. (F–G) HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag (F) and SHBs/R169A–Strep–Flag (G) and analyzed by Strep pull–down and WB as in (E).
    Human Hepatoma Cell Lines Hepg2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hepatoma cell lines hepg2/product/ATCC
    Average 99 stars, based on 1 article reviews
    human hepatoma cell lines hepg2 - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    ATCC hepg2 human hepatocellular carcinoma cell line
    Sangyod rice extract demonstrated a reduction in cytotoxicity and ROS levels in OA-induced <t>HepG2</t> cells. (A) Viability of HepG2 cells exposed to different concentrations of Sangyod rice extract. (B) Viability of Sangyod rice extract treatment after OA-induced HepG2 cells. (C) ROS generation in OA-induced HepG2 cells. Results are presented as the mean ± SEM from four independent biological experiments ( n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. * p < 0.05 compared to the control group, and # p < 0.05 compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.
    Hepg2 Human Hepatocellular Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hepg2 human hepatocellular carcinoma cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    hepg2 human hepatocellular carcinoma cell line - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    ATCC hepg2 cells
    Knockdown of L-FABP mitigated F-53B-induced damage in <t>HepG2</t> cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.
    Hepg2 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hepg2 cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    hepg2 cells - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    ATCC hepg2 human hepatocellular carcinoma cells
    Knockdown of L-FABP mitigated F-53B-induced damage in <t>HepG2</t> cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.
    Hepg2 Human Hepatocellular Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hepg2 human hepatocellular carcinoma cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    hepg2 human hepatocellular carcinoma cells - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    86
    Procell Inc human liver cancer cell line hepg2
    Knockdown of L-FABP mitigated F-53B-induced damage in <t>HepG2</t> cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.
    Human Liver Cancer Cell Line Hepg2, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human liver cancer cell line hepg2/product/Procell Inc
    Average 86 stars, based on 1 article reviews
    human liver cancer cell line hepg2 - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    86
    Procell Inc hepg2 cells
    Knockdown of L-FABP mitigated F-53B-induced damage in <t>HepG2</t> cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.
    Hepg2 Cells, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hepg2 cells/product/Procell Inc
    Average 86 stars, based on 1 article reviews
    hepg2 cells - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    86
    Procell Inc hepg2 human hcc cell line
    Knockdown of L-FABP mitigated F-53B-induced damage in <t>HepG2</t> cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.
    Hepg2 Human Hcc Cell Line, supplied by Procell Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hepg2 human hcc cell line/product/Procell Inc
    Average 86 stars, based on 1 article reviews
    hepg2 human hcc cell line - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    86
    Korean Cell Line Bank human hepatoblastoma cell line hepg2
    Knockdown of L-FABP mitigated F-53B-induced damage in <t>HepG2</t> cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.
    Human Hepatoblastoma Cell Line Hepg2, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human hepatoblastoma cell line hepg2/product/Korean Cell Line Bank
    Average 86 stars, based on 1 article reviews
    human hepatoblastoma cell line hepg2 - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    86
    Korean Cell Line Bank hepg2 human liver hepatocellular carcinoma cells
    Knockdown of L-FABP mitigated F-53B-induced damage in <t>HepG2</t> cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.
    Hepg2 Human Liver Hepatocellular Carcinoma Cells, supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hepg2 human liver hepatocellular carcinoma cells/product/Korean Cell Line Bank
    Average 86 stars, based on 1 article reviews
    hepg2 human liver hepatocellular carcinoma cells - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    Image Search Results


    SHBs is symmetrically dimethylated at arginine 169. (A–C) Huh7 and HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or Strep–Flag control. Strep pull–down (IP:Strep) was performed, followed by Western blot (WB) with antibodies against (A) monomethylarginine (MMA), (B) asymmetric dimethylarginine (ADMA), or (C) symmetric dimethylarginine (SDMA). SHBs in the IP fraction and SHBs/β–actin in input lysates are shown as controls. (D) Cells expressing SHBs–Strep–Flag were treated with adenosine dialdehyde (ADOX, 40 μM) for 36 h, followed by Strep pull–down and WB for SDMA and SHBs. Densitometric ratios (SDMA/IP–SHBs and SHBs/β–actin) are shown above/below the blots. (E) Huh7 cells were transfected with plasmids encoding SHBs–Strep–Flag or the indicated R→K mutants (R73K, R78K, R79K, R169K). SDMA on immunoprecipitated SHBs was assessed by Strep pull–down and WB; densitometric SDMA/IP–SHBs ratios are shown above the blots. (F–G) HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag (F) and SHBs/R169A–Strep–Flag (G) and analyzed by Strep pull–down and WB as in (E).

    Journal: Tumour Virus Research

    Article Title: PRMT5–mediated symmetric dimethylation of SHBs at Arg169 stabilizes SHBs and promotes angiogenesis and tumor growth

    doi: 10.1016/j.tvr.2026.200340

    Figure Lengend Snippet: SHBs is symmetrically dimethylated at arginine 169. (A–C) Huh7 and HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or Strep–Flag control. Strep pull–down (IP:Strep) was performed, followed by Western blot (WB) with antibodies against (A) monomethylarginine (MMA), (B) asymmetric dimethylarginine (ADMA), or (C) symmetric dimethylarginine (SDMA). SHBs in the IP fraction and SHBs/β–actin in input lysates are shown as controls. (D) Cells expressing SHBs–Strep–Flag were treated with adenosine dialdehyde (ADOX, 40 μM) for 36 h, followed by Strep pull–down and WB for SDMA and SHBs. Densitometric ratios (SDMA/IP–SHBs and SHBs/β–actin) are shown above/below the blots. (E) Huh7 cells were transfected with plasmids encoding SHBs–Strep–Flag or the indicated R→K mutants (R73K, R78K, R79K, R169K). SDMA on immunoprecipitated SHBs was assessed by Strep pull–down and WB; densitometric SDMA/IP–SHBs ratios are shown above the blots. (F–G) HepG2 cells were transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag (F) and SHBs/R169A–Strep–Flag (G) and analyzed by Strep pull–down and WB as in (E).

    Article Snippet: Human hepatoma cell lines HepG2 (ATCC, HB–8065) and Huh7 (JCRB, JCRB0403), endothelial cell line EA.hy926 (ATCC, CRL–2922TM), and HEK293T cells (ATCC, CRL–3216) were obtained from the American Type Culture Collection (ATCC) and the Japanese Collection of Research Bioresources Cell Bank (JCRB, Japan).

    Techniques: Transfection, Control, Western Blot, Expressing, Immunoprecipitation

    PRMT interacts with SHBs. (A) Huh7 cells were co–transfected with plasmids encoding SHBs–Strep–Flag (or Strep–Flag control) together with Flag–PRMT9. Strep pull–down was followed by WB with anti–Flag and anti–SHBs to assess co–precipitation. (B) Huh7 and HepG2 cells were co–transfected with plasmids encoding SHBs–Strep–Flag (or Strep–Flag control) together with Flag–PRMT5 and analyzed by Strep pull–down and WB as in (A). (C) Huh7 and HepG2 cells were co–transfected with plasmids encoding Strep–Flag–PRMT5 and SHBs–myc. Strep pull–down was performed and precipitates were immunoblotted for SHBs and Flag to validate the interaction. (D) Direct interaction between SHBs and PRMT5 was tested by GST pull–down. Purified GST or GST–PRMT5 (Coomassie–stained gel, left) was incubated with in vitro–translated SHBs–Flag, and bound SHBs was detected by WB using anti–Flag (right). (E) Confocal microscopy showing subcellular localization of SHBs (red) and PRMT5 (green) with nuclear DAPI staining (blue). Merged images and a representative line–scan fluorescence intensity profile (right) are shown.

    Journal: Tumour Virus Research

    Article Title: PRMT5–mediated symmetric dimethylation of SHBs at Arg169 stabilizes SHBs and promotes angiogenesis and tumor growth

    doi: 10.1016/j.tvr.2026.200340

    Figure Lengend Snippet: PRMT interacts with SHBs. (A) Huh7 cells were co–transfected with plasmids encoding SHBs–Strep–Flag (or Strep–Flag control) together with Flag–PRMT9. Strep pull–down was followed by WB with anti–Flag and anti–SHBs to assess co–precipitation. (B) Huh7 and HepG2 cells were co–transfected with plasmids encoding SHBs–Strep–Flag (or Strep–Flag control) together with Flag–PRMT5 and analyzed by Strep pull–down and WB as in (A). (C) Huh7 and HepG2 cells were co–transfected with plasmids encoding Strep–Flag–PRMT5 and SHBs–myc. Strep pull–down was performed and precipitates were immunoblotted for SHBs and Flag to validate the interaction. (D) Direct interaction between SHBs and PRMT5 was tested by GST pull–down. Purified GST or GST–PRMT5 (Coomassie–stained gel, left) was incubated with in vitro–translated SHBs–Flag, and bound SHBs was detected by WB using anti–Flag (right). (E) Confocal microscopy showing subcellular localization of SHBs (red) and PRMT5 (green) with nuclear DAPI staining (blue). Merged images and a representative line–scan fluorescence intensity profile (right) are shown.

    Article Snippet: Human hepatoma cell lines HepG2 (ATCC, HB–8065) and Huh7 (JCRB, JCRB0403), endothelial cell line EA.hy926 (ATCC, CRL–2922TM), and HEK293T cells (ATCC, CRL–3216) were obtained from the American Type Culture Collection (ATCC) and the Japanese Collection of Research Bioresources Cell Bank (JCRB, Japan).

    Techniques: Transfection, Control, Purification, Staining, Incubation, In Vitro, Confocal Microscopy, Fluorescence

    PRMT5 stabilizes SHBs protein expression in an Arg169–dependent manner. (A) Huh7 and HepG2 cells were co–transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag together with increasing amounts of Flag–PRMT5 (0, 1, 3 μg). Whole–cell lysates were immunoblotted for SHBs, Flag, and β–actin; SHBs/β–actin ratios are shown above the blots. (B) Cells expressing SHBs–Strep–Flag or SHBs/R169K–Strep–Flag were transfected with NC or PRMT5 siRNAs (#1, #2). Lysates were immunoblotted for SHBs, PRMT5, and β–actin; SHBs/β–actin ratios are shown. (C–D) Cycloheximide (CHX) chase assays in (C) Huh7 and (D) HepG2 cells. Cells expressing SHBs or SHBs/R169K with vector or Flag–PRMT5 were treated with CHX for the indicated times (0–120 min), followed by WB for SHBs, Flag, and β–actin. Plots show relative SHBs levels normalized to time 0 with fitted linear regression (equations displayed). (E) HepG2 cells were co–transfected with plasmids encoding SHBs–Strep, HA–K48Ub, together with or without Flag–PRMT5, and treated with MG132 (20 μM) for 8 h, the ubiquitination levels of SHBs was evaluated via ubiquitination assay analysis. (F) HepG2 cells were co–transfected with plasmid encoding SHBs–Strep and TRIM21–myc (or control vector) and Flag–PRMT5 (or control vector), the cell lysates were subjected to immunoprecipitation using Strep–Tactin and analyzed by immunoblotting.

    Journal: Tumour Virus Research

    Article Title: PRMT5–mediated symmetric dimethylation of SHBs at Arg169 stabilizes SHBs and promotes angiogenesis and tumor growth

    doi: 10.1016/j.tvr.2026.200340

    Figure Lengend Snippet: PRMT5 stabilizes SHBs protein expression in an Arg169–dependent manner. (A) Huh7 and HepG2 cells were co–transfected with plasmids encoding SHBs–Strep–Flag or SHBs/R169K–Strep–Flag together with increasing amounts of Flag–PRMT5 (0, 1, 3 μg). Whole–cell lysates were immunoblotted for SHBs, Flag, and β–actin; SHBs/β–actin ratios are shown above the blots. (B) Cells expressing SHBs–Strep–Flag or SHBs/R169K–Strep–Flag were transfected with NC or PRMT5 siRNAs (#1, #2). Lysates were immunoblotted for SHBs, PRMT5, and β–actin; SHBs/β–actin ratios are shown. (C–D) Cycloheximide (CHX) chase assays in (C) Huh7 and (D) HepG2 cells. Cells expressing SHBs or SHBs/R169K with vector or Flag–PRMT5 were treated with CHX for the indicated times (0–120 min), followed by WB for SHBs, Flag, and β–actin. Plots show relative SHBs levels normalized to time 0 with fitted linear regression (equations displayed). (E) HepG2 cells were co–transfected with plasmids encoding SHBs–Strep, HA–K48Ub, together with or without Flag–PRMT5, and treated with MG132 (20 μM) for 8 h, the ubiquitination levels of SHBs was evaluated via ubiquitination assay analysis. (F) HepG2 cells were co–transfected with plasmid encoding SHBs–Strep and TRIM21–myc (or control vector) and Flag–PRMT5 (or control vector), the cell lysates were subjected to immunoprecipitation using Strep–Tactin and analyzed by immunoblotting.

    Article Snippet: Human hepatoma cell lines HepG2 (ATCC, HB–8065) and Huh7 (JCRB, JCRB0403), endothelial cell line EA.hy926 (ATCC, CRL–2922TM), and HEK293T cells (ATCC, CRL–3216) were obtained from the American Type Culture Collection (ATCC) and the Japanese Collection of Research Bioresources Cell Bank (JCRB, Japan).

    Techniques: Expressing, Transfection, Plasmid Preparation, Ubiquitin Proteomics, Control, Immunoprecipitation, Western Blot

    Arg169 symmetric dimethylation is required for SHBs–driven angiogenesis and tumor growth. (A) WB analysis of SHBs and BIP expression in stably transduced Huh7 and HepG2 cells (Vector, SHBs, and SHBs/R169K). (B) ELISA measurement of VEGFA levels in the supernatants of Huh7/HepG2–Vector, Huh7/HepG2–SHBs, or Huh7/HepG2–SHBs/R169K cells. (C) Endothelial tube formation assay. EA.hy926 cells were cultured with conditioned media (CM) from Huh7 or HepG2 stable lines (Vector, SHBs, SHBs/R169K). Representative images and quantification of mesh numbers are shown. (D) Transwell migration assay. EA.hy926 cells were assessed for migration in response to CM from the indicated stable lines. Representative images and quantification of migrated cell numbers per field are shown. (E) Representative images of excised subcutaneous xenograft tumors derived from Huh7–Vector, Huh7–SHBs, or Huh7–SHBs/R169K cells. (F) Tumor growth curves (tumor volume over time) for the indicated xenograft groups. (G) Tumor weights at endpoint. (H) Representative immunohistochemical staining of xenograft tumors for CD31 and SHBs, with quantification of microvessel density (MVD) based on CD31 staining. Data are presented as mean ± SD; ∗ P < 0.05 as indicated.

    Journal: Tumour Virus Research

    Article Title: PRMT5–mediated symmetric dimethylation of SHBs at Arg169 stabilizes SHBs and promotes angiogenesis and tumor growth

    doi: 10.1016/j.tvr.2026.200340

    Figure Lengend Snippet: Arg169 symmetric dimethylation is required for SHBs–driven angiogenesis and tumor growth. (A) WB analysis of SHBs and BIP expression in stably transduced Huh7 and HepG2 cells (Vector, SHBs, and SHBs/R169K). (B) ELISA measurement of VEGFA levels in the supernatants of Huh7/HepG2–Vector, Huh7/HepG2–SHBs, or Huh7/HepG2–SHBs/R169K cells. (C) Endothelial tube formation assay. EA.hy926 cells were cultured with conditioned media (CM) from Huh7 or HepG2 stable lines (Vector, SHBs, SHBs/R169K). Representative images and quantification of mesh numbers are shown. (D) Transwell migration assay. EA.hy926 cells were assessed for migration in response to CM from the indicated stable lines. Representative images and quantification of migrated cell numbers per field are shown. (E) Representative images of excised subcutaneous xenograft tumors derived from Huh7–Vector, Huh7–SHBs, or Huh7–SHBs/R169K cells. (F) Tumor growth curves (tumor volume over time) for the indicated xenograft groups. (G) Tumor weights at endpoint. (H) Representative immunohistochemical staining of xenograft tumors for CD31 and SHBs, with quantification of microvessel density (MVD) based on CD31 staining. Data are presented as mean ± SD; ∗ P < 0.05 as indicated.

    Article Snippet: Human hepatoma cell lines HepG2 (ATCC, HB–8065) and Huh7 (JCRB, JCRB0403), endothelial cell line EA.hy926 (ATCC, CRL–2922TM), and HEK293T cells (ATCC, CRL–3216) were obtained from the American Type Culture Collection (ATCC) and the Japanese Collection of Research Bioresources Cell Bank (JCRB, Japan).

    Techniques: Expressing, Stable Transfection, Plasmid Preparation, Enzyme-linked Immunosorbent Assay, Endothelial Tube Formation Assay, Cell Culture, Transwell Migration Assay, Migration, Derivative Assay, Immunohistochemical staining, Staining

    Sangyod rice extract demonstrated a reduction in cytotoxicity and ROS levels in OA-induced HepG2 cells. (A) Viability of HepG2 cells exposed to different concentrations of Sangyod rice extract. (B) Viability of Sangyod rice extract treatment after OA-induced HepG2 cells. (C) ROS generation in OA-induced HepG2 cells. Results are presented as the mean ± SEM from four independent biological experiments ( n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. * p < 0.05 compared to the control group, and # p < 0.05 compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Journal: Food Chemistry: Molecular Sciences

    Article Title: Sangyod rice extract attenuates oleic acid–induced hepatic steatosis by modulating apoptotic, inflammatory, and lipid metabolic pathways

    doi: 10.1016/j.fochms.2026.100387

    Figure Lengend Snippet: Sangyod rice extract demonstrated a reduction in cytotoxicity and ROS levels in OA-induced HepG2 cells. (A) Viability of HepG2 cells exposed to different concentrations of Sangyod rice extract. (B) Viability of Sangyod rice extract treatment after OA-induced HepG2 cells. (C) ROS generation in OA-induced HepG2 cells. Results are presented as the mean ± SEM from four independent biological experiments ( n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. * p < 0.05 compared to the control group, and # p < 0.05 compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Article Snippet: The HepG2 human hepatocellular carcinoma cell line was procured from the American Type Culture Collection (Manassas, VA, USA) and nurtured in Dulbecco's modified Eagle's medium (Gibco, Waltham, MA, USA) enriched with 10% fetal bovine serum (Gibco, Waltham, MA, USA), 1% penicillin/streptomycin (Gibco, Waltham, MA, USA), and 1% l -glutamine (Gibco, Waltham, MA, USA).

    Techniques: Control

    Sangyod rice extract inhibited apoptosis in OA-induced HepG2 cells by suppressing the Bax and caspase-3 pathway. (A) Representative images of nuclei stained with Hoechst 33342. Images shown at ×20 magnification. Scale bar: 50 μm. (B) Percentage of apoptotic cells after treatment with Sangyod rice extract in OA-induced HepG2 cells. (C) Western blot analysis of Bax, Bcl-2, procaspase-3, and cleaved caspase-3. (D) Relative expression of Bax and Bcl-2. (E) Relative expression of procaspase 3, and cleaved caspase 3. Results are presented as the mean ± SEM from four independent biological experiments ( n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 compared to the control group, and #p < 0.05 compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Journal: Food Chemistry: Molecular Sciences

    Article Title: Sangyod rice extract attenuates oleic acid–induced hepatic steatosis by modulating apoptotic, inflammatory, and lipid metabolic pathways

    doi: 10.1016/j.fochms.2026.100387

    Figure Lengend Snippet: Sangyod rice extract inhibited apoptosis in OA-induced HepG2 cells by suppressing the Bax and caspase-3 pathway. (A) Representative images of nuclei stained with Hoechst 33342. Images shown at ×20 magnification. Scale bar: 50 μm. (B) Percentage of apoptotic cells after treatment with Sangyod rice extract in OA-induced HepG2 cells. (C) Western blot analysis of Bax, Bcl-2, procaspase-3, and cleaved caspase-3. (D) Relative expression of Bax and Bcl-2. (E) Relative expression of procaspase 3, and cleaved caspase 3. Results are presented as the mean ± SEM from four independent biological experiments ( n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 compared to the control group, and #p < 0.05 compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Article Snippet: The HepG2 human hepatocellular carcinoma cell line was procured from the American Type Culture Collection (Manassas, VA, USA) and nurtured in Dulbecco's modified Eagle's medium (Gibco, Waltham, MA, USA) enriched with 10% fetal bovine serum (Gibco, Waltham, MA, USA), 1% penicillin/streptomycin (Gibco, Waltham, MA, USA), and 1% l -glutamine (Gibco, Waltham, MA, USA).

    Techniques: Staining, Western Blot, Expressing, Control

    Sangyod rice extract attenuated inflammation in OA-induced HepG2 cells through inhibition of the NF-κB pathway. (A) TNF-α gene, (B) IL-1β gene, (C) IL-6 gene, (D) IL-10 gene. (E) Western blot analysis of NF-κB. (F) Relative expression of NF-κB protein. Results are presented as the mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Journal: Food Chemistry: Molecular Sciences

    Article Title: Sangyod rice extract attenuates oleic acid–induced hepatic steatosis by modulating apoptotic, inflammatory, and lipid metabolic pathways

    doi: 10.1016/j.fochms.2026.100387

    Figure Lengend Snippet: Sangyod rice extract attenuated inflammation in OA-induced HepG2 cells through inhibition of the NF-κB pathway. (A) TNF-α gene, (B) IL-1β gene, (C) IL-6 gene, (D) IL-10 gene. (E) Western blot analysis of NF-κB. (F) Relative expression of NF-κB protein. Results are presented as the mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Article Snippet: The HepG2 human hepatocellular carcinoma cell line was procured from the American Type Culture Collection (Manassas, VA, USA) and nurtured in Dulbecco's modified Eagle's medium (Gibco, Waltham, MA, USA) enriched with 10% fetal bovine serum (Gibco, Waltham, MA, USA), 1% penicillin/streptomycin (Gibco, Waltham, MA, USA), and 1% l -glutamine (Gibco, Waltham, MA, USA).

    Techniques: Inhibition, Western Blot, Expressing, Control

    Sangyod rice extract reduced lipid accumulation in OA-induced HepG2 cells. (A) Oil Red O staining was conducted on HepG2 cells, with red fat droplets indicating lipid accumulation. Images shown at ×20 magnification. Scale bar: 50 μm. (B) Percentage of lipid accumulation post Oil Red O extraction. (C) Levels of TG were measured using an assay kit. The data is displayed as mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Journal: Food Chemistry: Molecular Sciences

    Article Title: Sangyod rice extract attenuates oleic acid–induced hepatic steatosis by modulating apoptotic, inflammatory, and lipid metabolic pathways

    doi: 10.1016/j.fochms.2026.100387

    Figure Lengend Snippet: Sangyod rice extract reduced lipid accumulation in OA-induced HepG2 cells. (A) Oil Red O staining was conducted on HepG2 cells, with red fat droplets indicating lipid accumulation. Images shown at ×20 magnification. Scale bar: 50 μm. (B) Percentage of lipid accumulation post Oil Red O extraction. (C) Levels of TG were measured using an assay kit. The data is displayed as mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Article Snippet: The HepG2 human hepatocellular carcinoma cell line was procured from the American Type Culture Collection (Manassas, VA, USA) and nurtured in Dulbecco's modified Eagle's medium (Gibco, Waltham, MA, USA) enriched with 10% fetal bovine serum (Gibco, Waltham, MA, USA), 1% penicillin/streptomycin (Gibco, Waltham, MA, USA), and 1% l -glutamine (Gibco, Waltham, MA, USA).

    Techniques: Staining, Extraction, Control

    Effect of Sangyod rice extract on lipid metabolism in OA-induced HepG2 cells. (A) SREBP-1c gene (B) ACC gene, (C) FASN gene (D) CPT-1 A gene, (E) SCD1 gene, (F) MTTP gene. The data is displayed as mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Journal: Food Chemistry: Molecular Sciences

    Article Title: Sangyod rice extract attenuates oleic acid–induced hepatic steatosis by modulating apoptotic, inflammatory, and lipid metabolic pathways

    doi: 10.1016/j.fochms.2026.100387

    Figure Lengend Snippet: Effect of Sangyod rice extract on lipid metabolism in OA-induced HepG2 cells. (A) SREBP-1c gene (B) ACC gene, (C) FASN gene (D) CPT-1 A gene, (E) SCD1 gene, (F) MTTP gene. The data is displayed as mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Article Snippet: The HepG2 human hepatocellular carcinoma cell line was procured from the American Type Culture Collection (Manassas, VA, USA) and nurtured in Dulbecco's modified Eagle's medium (Gibco, Waltham, MA, USA) enriched with 10% fetal bovine serum (Gibco, Waltham, MA, USA), 1% penicillin/streptomycin (Gibco, Waltham, MA, USA), and 1% l -glutamine (Gibco, Waltham, MA, USA).

    Techniques: Control

    Effect of Sangyod rice extract on the expression of LPL-1, LPL-2, PGC-1α and PPARα in OA-induced HepG2 cells. (A) LPL-1 gene (B) LPL-2 gene, (C) PPARα gene (D) PGC-1α gene. The data is displayed as mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Journal: Food Chemistry: Molecular Sciences

    Article Title: Sangyod rice extract attenuates oleic acid–induced hepatic steatosis by modulating apoptotic, inflammatory, and lipid metabolic pathways

    doi: 10.1016/j.fochms.2026.100387

    Figure Lengend Snippet: Effect of Sangyod rice extract on the expression of LPL-1, LPL-2, PGC-1α and PPARα in OA-induced HepG2 cells. (A) LPL-1 gene (B) LPL-2 gene, (C) PPARα gene (D) PGC-1α gene. The data is displayed as mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Article Snippet: The HepG2 human hepatocellular carcinoma cell line was procured from the American Type Culture Collection (Manassas, VA, USA) and nurtured in Dulbecco's modified Eagle's medium (Gibco, Waltham, MA, USA) enriched with 10% fetal bovine serum (Gibco, Waltham, MA, USA), 1% penicillin/streptomycin (Gibco, Waltham, MA, USA), and 1% l -glutamine (Gibco, Waltham, MA, USA).

    Techniques: Expressing, Control

    Sangyod rice extract regulates lipid metabolism through the Akt and MAPK signaling pathways. (A) Western blot analysis of Akt, ERK1/2 amd p38 MAPK, (B) Relative expression of pERK/ERK protein, (C) Relative expression of p-p38/p38 protein, (D) Relative expression of pAkt/Akt protein. The data is displayed as mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Journal: Food Chemistry: Molecular Sciences

    Article Title: Sangyod rice extract attenuates oleic acid–induced hepatic steatosis by modulating apoptotic, inflammatory, and lipid metabolic pathways

    doi: 10.1016/j.fochms.2026.100387

    Figure Lengend Snippet: Sangyod rice extract regulates lipid metabolism through the Akt and MAPK signaling pathways. (A) Western blot analysis of Akt, ERK1/2 amd p38 MAPK, (B) Relative expression of pERK/ERK protein, (C) Relative expression of p-p38/p38 protein, (D) Relative expression of pAkt/Akt protein. The data is displayed as mean ± SEM from four independent biological experiments (n = 4). One-way ANOVA followed by Tukey ' s post hoc test was used to determine statistical significance. *p < 0.05 indicates significance compared to the control group, while #p < 0.05 denotes significance compared to the OA group. Groups: Control (0.1% DMSO); OA (0.4 mM), oleic acid-induced HepG2 cells without treatment; SR 10, OA-induced HepG2 cells +10 μg/mL Sangyod rice extract; SR 50, OA-induced HepG2 cells +50 μg/mL Sangyod rice extract; SR 100, OA-induced HepG2 cells +100 μg/mL Sangyod rice extract.

    Article Snippet: The HepG2 human hepatocellular carcinoma cell line was procured from the American Type Culture Collection (Manassas, VA, USA) and nurtured in Dulbecco's modified Eagle's medium (Gibco, Waltham, MA, USA) enriched with 10% fetal bovine serum (Gibco, Waltham, MA, USA), 1% penicillin/streptomycin (Gibco, Waltham, MA, USA), and 1% l -glutamine (Gibco, Waltham, MA, USA).

    Techniques: Protein-Protein interactions, Western Blot, Expressing, Control

    Knockdown of L-FABP mitigated F-53B-induced damage in HepG2 cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.

    Journal: iScience

    Article Title: F-53B exposure accelerates progression from preexisting fatty liver to non-alcoholic steatohepatitis and hepatic fibrosis

    doi: 10.1016/j.isci.2026.115675

    Figure Lengend Snippet: Knockdown of L-FABP mitigated F-53B-induced damage in HepG2 cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.

    Article Snippet: HepG2 cells were authenticated by ATCC using STR profiling and tested negative for mycoplasma contamination.

    Techniques: Knockdown, Binding Assay, Western Blot, Control, Expressing, Negative Control, MANN-WHITNEY

    Knockdown of L-FABP mitigated F-53B-induced damage in HepG2 cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.

    Journal: iScience

    Article Title: F-53B exposure accelerates progression from preexisting fatty liver to non-alcoholic steatohepatitis and hepatic fibrosis

    doi: 10.1016/j.isci.2026.115675

    Figure Lengend Snippet: Knockdown of L-FABP mitigated F-53B-induced damage in HepG2 cells (A) Liver-type fatty acid-binding protein (L-FABP) knockdown was confirmed by immunoblot analysis using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the loading control ( n = 6). (B) Calculated L-FABP/GAPDH ratio ( n = 6) based on the immunoblot results shown in (A). (C) Effects of different treatments on TG content in HepG2 cells ( n = 5). (D) Fold change of TG content in NC + F-53B/NC and L-FABP KD + F-53B/L-FABP KD groups ( n = 5). (E) Interleukin-6 (IL-6) expression in HepG2 cells following different treatments. (F) Relative IL-6 expression (IL-6/GAPDH) ( n = 6). (G) Fold change of IL-6 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). (H) Transforming growth factor β1 (TGF-β1) expression in HepG2 cells following different treatments. (I) Relative TGF-β1 expression (TGF-β1/GAPDH) ( n = 6). (J) Fold change of TGF-β1 (relative to respective control) in NC vs. L-FABP KD groups with F-53B treatment ( n = 6). NC, negative control siRNA group. NC + F-53B, NC with 5 mg/L F-53B group. L-FABP KD, L-FABP-knockdown group. L-FABP KD + F-53B, L-FABP KD with 5 mg/L F-53B group. Data are presented as mean ± SEM. The significance of differences between two groups was determined using the Mann-Whitney U test, and is indicated by hash symbols: # p < 0.05, ## p < 0.01.

    Article Snippet: HepG2 human hepatocellular carcinoma cells (ATCC, HB-8065) were maintained in a humidified incubator at 37 °C with 5% CO 2 .

    Techniques: Knockdown, Binding Assay, Western Blot, Control, Expressing, Negative Control, MANN-WHITNEY